These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1762049)

  • 1. [Research and development of pravastatin].
    Kishida Y; Naito A; Iwado S; Terahara A; Tsujita Y
    Yakugaku Zasshi; 1991 Sep; 111(9):469-87. PubMed ID: 1762049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and molecular approaches for production of pravastatin, a potent cholesterol-lowering drug.
    Serizawa N
    Biotechnol Annu Rev; 1996; 2():373-89. PubMed ID: 9704102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus. ML-236B (compactin) induces a cytochrome P-450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase.
    Matsuoka T; Miyakoshi S; Tanzawa K; Nakahara K; Hosobuchi M; Serizawa N
    Eur J Biochem; 1989 Oct; 184(3):707-13. PubMed ID: 2509201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
    Watanabe Y; Ito T; Shiomi M; Tsujita Y; Kuroda M; Arai M; Fukami M; Tamura A
    Biochim Biophys Acta; 1988 Jun; 960(3):294-302. PubMed ID: 3132979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits.
    Shiomi M; Ito T
    Metabolism; 1994 May; 43(5):559-64. PubMed ID: 8177044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallization and preliminary X-ray diffraction analysis of cytochrome P450sca-2 from Streptomyces carbophilus involved in production of pravastatin sodium, a tissue-selective inhibitor of HMG-CoA reductase.
    Ito S; Matsuoka T; Watanabe I; Kagasaki T; Serizawa N; Hata T
    Acta Crystallogr D Biol Crystallogr; 1999 Jun; 55(Pt 6):1209-11. PubMed ID: 10329788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species.
    Tsujita Y; Kuroda M; Shimada Y; Tanzawa K; Arai M; Kaneko I; Tanaka M; Masuda H; Tarumi C; Watanabe Y
    Biochim Biophys Acta; 1986 Jun; 877(1):50-60. PubMed ID: 3636158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
    Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A
    Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
    Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits.
    Saga A; Okura H; Soeda M; Tani J; Fumimoto Y; Komoda H; Moriyama M; Moriyama H; Yamashita S; Ichinose A; Daimon T; Hayakawa T; Matsuyama A
    Biochem Biophys Res Commun; 2011 Aug; 412(1):50-4. PubMed ID: 21806964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits.
    Amorosa LF; Rozovski SJ; Ananthakrishnan R; Coly E; AlHinai A; Martucci C; Schneider SH; Shimamura T; Khachadurian AK
    Jpn Heart J; 1992 Jul; 33(4):451-63. PubMed ID: 1453550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pravastatin: a new drug for the treatment of hypercholesterolemia.
    Jungnickel PW; Cantral KA; Maloley PA
    Clin Pharm; 1992 Aug; 11(8):677-89. PubMed ID: 1511541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin sodium, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases serum total cholesterol in Japanese White rabbits by two different mechanisms.
    Miyazaki A; Koga T
    Atherosclerosis; 2002 Jun; 162(2):299-306. PubMed ID: 11996949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats.
    Fujioka T; Nara F; Tsujita Y; Fukushige J; Fukami M; Kuroda M
    Biochim Biophys Acta; 1995 Jan; 1254(1):7-12. PubMed ID: 7811749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits.
    Kroon AA; Stalenhoef AF; Buikema H; Demacker PN; de Wilde PC; Leijten PA; van Gilst WH
    Atherosclerosis; 1993 Nov; 103(2):221-30. PubMed ID: 8292097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits.
    Kuroda M; Matsumoto A; Itakura H; Watanabe Y; Ito T; Shiomi M; Fukushige J; Nara F; Fukami M; Tsujita Y
    Jpn J Pharmacol; 1992 May; 59(1):65-70. PubMed ID: 1507659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
    Serizawa N; Matsuoka T
    Biochim Biophys Acta; 1991 Jun; 1084(1):35-40. PubMed ID: 1905157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular approaches for production of pravastatin, a HMG-CoA reductase inhibitor: transcriptional regulation of the cytochrome p450sca gene from Streptomyces carbophilus by ML-236B sodium salt and phenobarbital.
    Watanabe I; Serizawa N
    Gene; 1998 Mar; 210(1):109-16. PubMed ID: 9524240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.